Warning: The NCBI web site requires JavaScript to function. more...
An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Biochemical Assay from US Patent US20240293380: "PROTEASE INHIBITORS AND METHODS OF USE"
Assay data:74 Active, 60 Activity ≤ 1 µM, 75 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMRelated BioAssays by Target
% Enzyme Activity of SARS-CoV2-Plpro in the Reaction Biology protease panel at 1.0 M
Assay data:1 Active, 1 Activity ≤ 1 µM, 1 Tested
Functional biochemical assay to identify treatments for viral infectious disease that targets SARS-COV-2 nsp3 macrodomain, whereby the mechanism of action displaces an ADP-Ribose modified peptide from the binding site. Utilizing a time-resolved fluorescence method to measure binding by reading the emitted fluorescence intensity in two wavelengths. This assay is characterized the relative potency of inhibitors as % of inhibition, it is modified from https://doi.org/10.1126/sciadv.abf8711 and has been performed by Weizmann Institute of Science.
Assay data:358 Tested
SummaryRelated BioAssays by Target
Functional biochemical assay to identify treatments for viral infectious disease that targets SARS-COV-2 nsp3 macrodomain, whereby the mechanism of action inhibits ADP-Ribose hydrolase activity. Utilizing an enzymatic assay to monitor the conversion of alpha-NAD+ to ADP-Ribose and nicotinamide. ADP-ribose was quantified by LC-MS/MS after precipitation of proteins. This assay is characterized the relative potency of inhibitors as IC50 and has been performed by Weizmann Institute of Science.
Assay data:14 Active, 10 Activity ≤ 1 µM, 17 Tested
Functional biochemical assay to identify treatments for viral infectious disease that targets SARS-COV-2 nsp3 macrodomain, whereby the mechanism of action displaces an ADP-Ribose modified peptide from the binding site. Utilizing a time-resolved fluorescence method to measure binding by reading the emitted fluorescence intensity in two wavelengths. This assay is characterized the relative potency of inhibitors as IC50, it is modified from https://doi.org/10.1126/sciadv.abf8711, and has been performed by Weizmann Institute of Science.
Assay data:308 Active, 157 Activity ≤ 1 µM, 765 Tested
Binding affinity to recombinant SARS-CoV-2 Nsp9 at 50 uM by Mass spectrometry analysis relative to control
Assay data:7 Tested
SummaryPubMed CitationRelated BioAssays by Target
Binding affinity to recombinant SARS-CoV-2 Nsp9 at 10 uM by Mass spectrometry analysis relative to control
Binding affinity to SARS-CoV-2 Nsp9 at 25 uM by LC-MS/MS analysis relative to control
Assay data:2 Active, 2 Tested
SummaryCompounds, ActivePubMed CitationRelated BioAssays by Target
Binding affinity to recombinant SARS-CoV-2 Nsp9 at 10 to 50 uM by Mass spectrometry analysis
Assay data:5 Tested
Binding affinity to recombinant SARS-CoV-2 Nsp9 assessed as dissociation constant by Mass spectrometry analysis
Assay data:1 Active, 2 Tested
Binding affinity to recombinant SARS-CoV-2 Nsp9 at 50 uM by Mass spectrometry analysis
Assay data:1 Active, 1 Tested
Inhibition of SARS-CoV-2 3CL protease using SEQ peptide as substrate pre-incubated for 30 min followed by substrate addition measured after 4 hrs by FRET assay
Assay data:6 Active, 6 Activity ≤ 1 µM, 6 Tested
SummaryCompounds, ActiveCompounds, activity ≤ 1 µMPubMed CitationRelated BioAssays by Target
Inhibition of SARS-Cov-2 Main protease at <=500 uM by FRET assay
Assay data:10 Tested
Uncompetitive inhibition of SARS-Cov-2 Main protease by Lineweaver-Burk plot analysis
Inhibition of SARS-Cov-2 Main protease by FRET assay
Assay data:14 Tested
Binding affinity to SARS-CoV-1 papain-like protease assessed as inhibition constant
Inhibition of SARS-CoV-2 papain-like protease
Assay data:6 Active, 4 Activity ≤ 1 µM, 19 Tested
Inhibition of SARS-CoV-1 papain-like protease
Assay data:4 Active, 4 Activity ≤ 1 µM, 5 Tested
Inhibition of SARS-CoV-2 3CLpro in presence of DTT at 20 uM incubated for 4 hrs relative to control
Assay data:9 Tested
Inhibition of SARS-CoV-2 3CLpro incubated for 4 hrs
Assay data:5 Active, 2 Activity ≤ 1 µM, 6 Tested
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on